These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 10475181)

  • 21. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators.
    Lagerqvist B; Säfström K; Ståhle E; Wallentin L; Swahn E;
    J Am Coll Cardiol; 2001 Jul; 38(1):41-8. PubMed ID: 11451294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease; the FRISC II ECG substudy. The Fast Revascularisation during InStability in Coronary artery disease.
    Diderholm E; Andrén B; Frostfeldt G; Genberg M; Jernberg T; Lagerqvist B; Lindahl B; Wallentin L
    Eur Heart J; 2002 Jan; 23(1):41-9. PubMed ID: 11741361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous multilead ST-monitoring identifies patients with unstable coronary artery disease who benefit from extended antithrombotic treatment.
    Jernberg T; Abrahamsson P; Lindahl B; Johanson P; Wallentin L; Dellborg M
    Eur Heart J; 2002 Jul; 23(14):1093-101. PubMed ID: 12090747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early aggressive treatment of unstable angina without on-site cardiac surgical facilities: a prospective study of acute and long-term outcome.
    Ferrero V; Steffenino G; Meinardi F; Conte E; Deorsola A; Vado A; Racca E; Dellavalle A; Ribichini F; Menardi E; Uslenghi E
    G Ital Cardiol; 1998 Feb; 28(2):112-9. PubMed ID: 9534050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
    N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
    Husted S; Kher A
    Ann Med; 2000 Dec; 32 Suppl 1():53-9. PubMed ID: 11209983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Long-term administration of Dalteparin in unstable coronary syndrome. FRISC II study opens novel therapeutic perspectives. Fragmin and Fast Revascularization during Instability in Coronary Artery Disease].
    Arnheim K
    Internist (Berl); 2000 Jan; 41(1):A35-6. PubMed ID: 10712085
    [No Abstract]   [Full Text] [Related]  

  • 28. Improving outcomes in acute coronary syndromes--the FRISC II trial.
    Kontny F
    Clin Cardiol; 2001 Mar; 24(3 Suppl):I3-7. PubMed ID: 11286312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.
    Norhammar A; Malmberg K; Diderholm E; Lagerqvist B; Lindahl B; Rydén L; Wallentin L
    J Am Coll Cardiol; 2004 Feb; 43(4):585-91. PubMed ID: 14975468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial.
    TIME Investigators
    Lancet; 2001 Sep; 358(9286):951-7. PubMed ID: 11583747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial.
    Janzon M; Levin LA; Swahn E;
    Heart; 2003 Mar; 89(3):287-92. PubMed ID: 12591833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data.
    Fox KA; Clayton TC; Damman P; Pocock SJ; de Winter RJ; Tijssen JG; Lagerqvist B; Wallentin L;
    J Am Coll Cardiol; 2010 Jun; 55(22):2435-45. PubMed ID: 20359842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.
    Lindahl B; Toss H; Siegbahn A; Venge P; Wallentin L
    N Engl J Med; 2000 Oct; 343(16):1139-47. PubMed ID: 11036119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of an early invasive strategy on ischemia and exercise tolerance among patients with unstable coronary artery disease.
    Diderholm E; Andrén B; Frostfeldt G; Genberg M; Jernberg T; Lagerqvist B; Lindahl B; Wallentin L
    Am J Med; 2003 Dec; 115(8):606-12. PubMed ID: 14656612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease.
    Klein W; Buchwald A; Hillis WS; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
    Am J Cardiol; 1997 Sep; 80(5A):30E-34E. PubMed ID: 9296467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive treatment in unstable coronary artery disease promotes health-related quality of life: results from the FRISC II trial.
    Janzon M; Levin LA; Swahn E
    Am Heart J; 2004 Jul; 148(1):114-21. PubMed ID: 15215800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study.
    Lancet; 1997 May; 349(9063):1429-35. PubMed ID: 9164316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of low molecular weight heparin to predict clinical outcome in patients with unstable angina that had undergone percutaneous coronary intervention.
    Hong YJ; Jeong MH; Lee SH; Park OY; Kim JH; Kim W; Rhew JY; Ahn YK; Cho JG; Park JC; Suh SP; Ahn BH; Kim SH; Kang JC
    Korean J Intern Med; 2003 Sep; 18(3):167-73. PubMed ID: 14619386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical characteristics, in-hospital outcomes and predictors of in-hospital mortality in patients with acute coronary syndromes without persistent ST-segment elevation assigned to early invasive treatment strategy].
    Szyguła-Jurkiewicz B; Wojnicz R; Trzeciak P; Niklewski T; Zembala M; Poloński L
    Przegl Lek; 2005; 62(5):265-9. PubMed ID: 16334529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term management--the way forward?
    Wallentin L
    Clin Cardiol; 2000 Jan; 23 Suppl 1(Suppl):I13-7. PubMed ID: 10680039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.